CLINICAL STUDIES
Kamari Pharma is well positioned to treat extremely debilitating rare dermatology diseases and itch. We develop effective disease modifying treatments for patients with great unmet needs.
PATIENTS
The Palmoplantar Keratodermas Disease
The Palmoplantar Keratodermas (PPKs), are a group of rare skin conditions that result from various mutations in several epidermal genes.
The Lichen Simplex Chronicus Disease
A topical cream is developed for the relief of itch associated with Lichen simplex chronicus (LSC).
Lichen simplex chronicus (LSC) is a chronic pruritic condition.
Palmoplantar Keratodermas
The Palmoplantar Keratodermas (PPKs), are a group of rare skin conditions that result from various mutations in several epidermal genes. Mild to moderate PPK’s are characterized by thickening of the skin on the palms and soles leading to great discomfort, itch and pain. The PPKs include diseases such as Punctuate PPK type 1 (PPPK1), Pachyonychia Congenita (PC) and Mal de Meleda, all of which have significant unmet medical need.
KM-001 is a novel pharmaceutical topical cream for the treatment of PPPK1 and PC.
Kamari pharma is currently enrolling patients for clinical study in PC and PPPK type- 1 patients
This is an open label clinical study to assess the safety and efficacy of KM-001 topical cream in 1% strength, in PPPK1 and PC patients. This Phase 1b study is a Proof-of-concept study, to evaluate the effectiveness of KM-001 in the treatment of PC and PPPK1 of adult patients.
The study is enrolling patients currently in Israel.
Lichen simplex chronicus
A topical cream is developed for the relief of itch associated with Lichen simplex chronicus (LSC).
Lichen simplex chronicus (LSC) is a chronic pruritic condition characterized by areas of thickened skin resulting from repeated rubbing or scratching. It may present with associated dryness, scaling, or redness (erythema). Commonly affected areas include the neck, ankles, extremities, scalp, and genital region. Currently, there is no effective therapy for LSC related itch, which negatively impacts the quality of life for approximately 12% of the adult population.
KM-001 is a novel pharmaceutical topical cream in development for the treatment of LCS related itch.
Kamari pharma is currently enrolling patients for clinical study in Lichen Simplex Chronicus in Germany
This is a double blind, vehicle controlled , randomized clinical study to assess the safety and efficacy of KM-001 topical cream in 0.3% and 1% strength, in Lichen Simplex Chronicus patients.
This Phase 1b study is the first to determine if KM-001 is safe, and able to reduce the itch caused by Lichen Simplex Chronicus.
How to enroll?
First, make the decision if you are willing to participate in a clinical study . Discuss it with your close-ones. It is a personal and important decision.
Next, you can follow the link below to learn more about the study and how to enroll:
Eurofins bioskin – Rosenpark Research GmbH (Darmstadt) – Lichen simplex chronicus
Eurofins bioskin – ProDerma – Hautzentrum Dülmen (Dülmen) – Lichen simplex chronicus
Eurofins bioskin – Fachklinik Bad Bentheim (Bad Bentheim) – Lichen simplex chronicus
Eurofins bioskin – Rothhaar Studien (Berlin) – Lichen simplex chronicus
Eurofins bioskin – Dermatologie Quist (Mainz) – Lichen simplex chronicus
